Kai Schulze

The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties.

The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.

A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties.

The FAI protein of group C streptococci acts as a mucosal adjuvant by the specific targeting and activation of B cells.

Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.

Development and characterization of attenuated metabolic mutants of Bordetella bronchiseptica for applications in vaccinology.

Vaccine adjuvants: key tools for innovative vaccine design.

Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.

Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation.

Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination.

Rodents as pre-clinical models for predicting vaccine performance in humans.

Modeling Influenza Virus Infection: A Roadmap for Influenza Research.

Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions.

New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.

Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi.

Role of Autophagy in HIV-1 Matrix Protein p17-Driven Lymphangiogenesis.

Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation Pathway.

Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.

Self-replicating RNA vaccine functionality modulated by fine-tuning of polyplex delivery vehicle structure.

Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice.